Moreover, based on the promising experimental and preclinical data so far available, we believe that a better identification of the molecular mechanisms of the antitumor activity of natural ERβ ligands will likely improve the treatment strategies for melanoma patients. The gene discussed is ESR2; the disease is melanoma.